Ozempic maker Novo Nordisk downgraded to sell following 70% stock-price dive from peak
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday. This story matters for Finance & Markets readers tracking fund. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →